PDF(Pubmed)
Abstract：
Advanced gynecologic cancers have historically lacked effective treatment options. Recently, immune checkpoint inhibitors (ICIs) have been approved by the US Food and Drug Administration for the treatment of cervical cancer and endometrial cancer, offering durable responses for some patients. In addition, many immunotherapy strategies are under investigation for the treatment of earlier stages of disease or in other gynecologic cancers, such as ovarian cancer and rare gynecologic tumors. While the integration of ICIs into the standard of care has improved outcomes for patients, their use requires a nuanced understanding of biomarker testing, treatment selection, patient selection, response evaluation and surveillance, and patient quality of life considerations, among other topics. To address this need for guidance, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel of experts to develop a clinical practice guideline. The Expert Panel drew on the published literature as well as their own clinical experience to develop evidence- and consensus-based recommendations to provide guidance to cancer care professionals treating patients with gynecologic cancer.
摘要：
晚期妇科癌症历来缺乏有效的治疗选择。最近,免疫检查点抑制剂（ICIs）已被美国食品和药物管理局批准用于治疗宫颈癌和子宫内膜癌，为一些患者提供持久的反应。此外,许多免疫治疗策略正在研究中，用于治疗早期疾病或其他妇科癌症，如卵巢癌和罕见的妇科肿瘤。虽然将ICI纳入护理标准改善了患者的预后，它们的使用需要对生物标志物测试有细微的了解，治疗选择，患者选择,反应评估和监测，和患者生活质量的考虑，在其他主题中。为了满足这种指导的需要，癌症免疫治疗学会(SITC)召集了一个多学科专家小组,以制定临床实践指南.专家小组利用已发表的文献以及他们自己的临床经验来制定基于证据和共识的建议，为治疗妇科癌症患者的癌症护理专业人员提供指导。
